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Abstract
Background: Kidney disease is an important complication in HIV infected people, and this may be related to
infection or antiretroviral therapy (ART). Our aim is to assess renal function in HIV infected paediatric patients, who
may be particularly affected and are likely to take ART for longer than adults, and investigate the long term role of
Tenofovir Disoproxil Fumarate (TDF) alone or co-administered with Ritonavir-boosted Protease Inhibitors (PI).
Methods: Serum creatinine, phosphate and potassium levels, with estimated Glomerular Filtration Rate (eGFR), had
been prospectively evaluated for 2 years in a cohort of HIV infected children and adolescents (age 9-18) on ART,
and data analyzed according to the exposure to TDF or simultaneous TDF and PI.
Results: Forty-nine patients were studied (57% female, mean age 14). Sixty-three percent were treated with ART
containing TDF (Group A), and 37% without TDF (Group B); 47% with concomitant use of TDF and PI (Group C)
and 53% without this combination (Group D). The groups didn’t differ for age, gender or ethnicity. The median
creatinine increased in the entire cohort and in all the groups analyzed; eGFR decreased from 143.6 mL/min/1.73
m2 at baseline to 128.9 after 2 years (p = 0.006) in the entire cohort. Three patients presented a mild eGFR
reduction, all were on TDF+PI. Phosphatemia decreased significantly in the entire cohort (p = 0.0003) and in TDF
+PI group (p = 0.0128) after 2 years. Five patients (10%) developed hypophosphatemia (Division of Acquired
Immune Deficiency AE grade 1 or 2), and four of them were on TDF+PI.
Conclusions: Renal function decrease and hypophosphatemia occur over time in HIV infected children and
adolescents on ART. The association with co-administration of TDF and PI appears weak, and further studies are
warranted.
Background
Antiretroviral therapy (ART) has reduced morbidity and
mortality in HIV infected children as in adults [1,2], but
not much is known on the effect of long-term exposure
to ART in children, because registration studies have a
limited observation time and are often not focused on
adverse events related to drug interactions [3]. Kidney
disease is an important complication in HIV infected
people, and associated to increased risk of morbidity
and mortality, related to viral infection (as in HIV asso-
ciated nephropathy, HIVAN), or to ART [4].
Tenofovir Disoproxil Fumarate (TDF) is a Nucleotide
Reverse Transcriptase Inhibitor, which is considered a
component of recommended regimens in major Clinical
Guidelines for adults, for its efficacy, activity against
hepatitis B, and availability in co-formulation allowing a
single pill a day regimen [5]. TDF has a good safety pro-
file but several studies highlighted its association with
renal damage in adults, with cases of severe tubular dys-
function characterized by elevated creatinine, hypopho-
sphataemia, hypokalemia, and more rarely Fanconi
syndrome which may persist after withdrawal of the
drug [6-12].
TDF is not licensed in Europe in patients less than 18
years of age but, by 2010, it received Food and Drug
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Administration (FDA) approval for use in patients aged
12-18 years and weighing more than 35 kg. Nevertheless
TDF has been already used as salvage therapy in paedia-
tric patients for several years, often in association with
boosted Protease Inhibitors (PI), and few reports
described the use of this drug in children. Two studies
determined a favourable safety profile for this drug
[13,14] whereas renal toxicity and bone density loss
were reported by other studies both in adults and chil-
dren [15-18].
Renal toxicity seems related to the mechanism of
clearance of TDF which involves a glomerular filtration
and a tubular phase of active secretion. During the tub-
ular phase, Organic Anion Transporters (OAT1 and
OAT3) are involved in the intracellular accessing of
TDF, on the other hand, Multidrug Resistance asso-
ciated Protein (MRP2 and MRP4) regulate the extracel-
lular clearance of the drug [19]. Ritonavir and all PI,
could have a significant role as cofactor in the patho-
genesis of TDF-induced kidney damage. TDF clearance
is slower in subjects receiving PI [20], with an increase
of TDF-AUC ranging from 22 to 37% [21] and an accu-
mulation of toxic drug levels in tubular cells [22]. The
results of in vitro studies also suggest that protease inhi-
bitors may inhibit the function of the MRP2 and MRP4
membrane transporters, and therefore increase the tubu-
lar concentration of TDF, and thus mitochondrial toxi-
city [23].
Our aim is to evaluate renal function in HIV infected
paediatric patients on antiretroviral therapy (ART) and
for the first time in a controlled study, the role of TDF
and the concomitant use of TDF and PI.
Methods
A prospective observational study was conducted among
a cohort of HIV infected children and adolescents (< 18
years of age) on ART followed between 2008 and 2010
at Bambino Gesù Children Hospital of Rome, Italy. The
study was approved by the local Ethical Committee, and
informed consent obtained from the parents or guar-
dians of all participants. The aim of the study was to
investigate the role of TDF and concomitant use of TDF
and PI on renal function in HIV infected children and
adolescents. The cohort was therefore analyzed firstly
using two groups according to the exposure to TDF
(Group A: TDF) or not (Group B: no TDF). Secondly a
further analysis was performed according to the expo-
sure to concomitant use of TDF and PI (Group C: TDF
+PI) or not (Group D: no TDF+PI). Since TDF was
used only in drug experienced children older than nine,
we studied only patients above this age, in order to not
introduce any age-related bias. Data on gender, age, eth-
nicity, CD4 T cell count and HIV-RNA (with a value of
< 50 copies/mL defined as undetectable) were collected
at baseline. Renal function was assessed at baseline, and
after 1 and 2 years by evaluation of serum creatinine
(assessed with non-enzymatic CREA2 method, a modi-
fied version of Jaffé reaction), phosphate, and potassium,
and filtrate was estimated by eGFR (estimated Glomeru-
lar Filtration Rate) calculated with the Schwartz formula
(k*height (cm)/creatinine (mg/dl); with k = 0.55, or 0.70
in males over the age of 13 years). No change in the
analytical methods to measure serum creatinine or other
markers took place during the study period. Reduction
of renal function was classified according to the guide-
lines of the National Kidney Foundation: “mild” 60-89;
“moderate” 30-59; “severe” 15-29; “renal failure” < 15
ml/min per 1.73 m2. Hypophosphatemia was divided
into four grades according to Division of Acquired
Immune Deficiency (DAIDS) scale. For patients under
14 years old: “mild": 3.0-3.5; “moderate” 2.5-2.9; “severe”
1.5-2.4; “potentially life-threatening” < 1.5 mg/dL. For
patients older than 14: “mild": 2.5-3.0; “moderate” 2.0-
2.4; “severe” 1-1.9; “potentially life-threatening” less than
1.0 mg/dL.
Data for continuous variables were expressed as mean
and standard deviation (SD) if normally distributed, or
median and Inter-Quartile Range (IQR) if not normally
distributed. Categorical data were showed as counts and
percentages. Analysis was conducted using Epi Info ver-
sion 3.5.1 (Centers for Diseases Control, Atlanta) or
GraphPad Prism version 5 for Windows (GraphPad
Software, San Diego California USA). Statistical analysis
of baseline variables was carried out for continuous data
with either ANOVA method for Analysis of Variance
for normal distributed data, or Mann-Whitney test for
non-normal distributed data, whereas chi-squared or
Fisher exact tests were used for categorical data. Ana-
lyses of variables of renal function were performed with
non-parametric Friedman test for comparison of values
of baseline, first and second year in each group, with
Wilcoxon matched-paired signed rank test for compari-
son of two time points, and with Mann-Whitney for
analysis of values of Group A versus Group B, and
values of Group C versus Group D at each time point.
A two tailed P value of less than 0.05 was considered
significant in all the analysis.
We expected an enrollment of about fifty patients, and
about two-thirds exposed to TDF, and half to TDF + PI.
Therefore, for eGFR analysis, the power to detect a dif-
ference of 15 mL/min/1.73 m2, considering a 95% Con-
fidence Interval, and assuming a Standard Deviation of
20, was 96% in the whole cohort, 86% in Group A, 59%
in the group B; 76% in the groups C and D. The power
to detect a difference of 15 mL/min/1.73 m2 between
Group A and B is 71%, and 76% between Group C and
D. Regarding phosphatemia, the power to detect a dif-
ference of 0.5 mg/dL considering a 95% Confidence
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Interval, and assuming a Standard Deviation of 0.7, was
95% in the whole cohort, 83% in the Group A, 55% in
the group B; 71% in groups C and D. The power to
detect a difference of 0.5 mg/dL between Group A and
B was 67%, and 71% between Group C and D.
Results
Forty-nine patients (9-18 year old) were studied. They
had a mean age of 13.6 years, and 28 (57%) were female.
The mean CD4% value was 27.1 (± 10.2), corresponding
to value of 565 cells/μL; 47% had HIV-RNA undetect-
able, and 39% of patients had a history of CDC (Center
for Disease Control) class C clinical diagnosis, and no
patients had creatinine > 1 mg/dL at baseline. None of
the patients was treatment naive.
Sixty-three percent were treated with antiretroviral
(ARV) regimens containing Tenofovir (Group A: TDF),
and 37% without TDF (Group B: No TDF).
Forty-seven percent were treated with regimens con-
taining both TDF and PI (Group C: TDF+PI), and 53%
without this combination (Group D: No TDF+PI). Spe-
cifically, 16% of patients were on TDF without PI, 20%
were with PI but alternative NRTIs, and 16% with other
regimens containing neither TDF nor PI. The children
didn’t differ for age, gender, frequency of undetectable
HIV-RNA, or ethnicity (p > 0.05 for all comparisons)
both between Group A and Group B, and between
Group C and D. CD4 resulted lower in group A and
Group C if compared to Group B and D respectively
(Table 1).
As shown in Figure 1, in the entire cohort there was a
significant increase of serum creatinine, from a median
of 0.62 mg/dL at baseline to 0.73 mg/dL (p < 0.0001)
after 2 years; eGFR decrease from a median of 143.6 at
baseline to 135.6 at 1 year, and 128.9 ml/min per 1.73
m2 at 2 years (p = 0.006). The value of phosphatemia
decreased significantly from 4.4 at baseline to 4.0 at 1
year (p = 0.0301) and to 3.8 mg/dl at 2 years (p =
0.0003). The median of potassiemia in the entire cohort
during the study period didn’t vary significantly.
The creatinine increased significantly after 2 years in
each of the groups analyzed, from +0.10 in Group A
and C to +0.16 mg/dL in Group B. There were no sig-
nificant differences between Group A and B, and Group
C and D.
The eGFR decreased after 2 years in all groups, signifi-
cantly in Group B (-23.8 ml/min per 1.73 m2, p = 0.012)
and Group D (-19.1, p = 0.02). There were no signifi-
cant differences between Group A and B, and Group C
and D. Among the subgroups we observed that 7
patients on TDF+PI, 2 on PI and not in TDF, 1 in TDF
and not PI, and 2 not taking nor TDF nor PI showed an
increase in eGFR during the study period. On the other
hand only 1 patient on TDF remained stable and all the
others (37 patients) showed a decrease in eGFR. Three
patients developed a mild reduction in glomerular filtra-
tion rate (60-89 ml/min per 1.73 m2), all were treated
with both TDF and PI. Among these patients none
received any other nephrotoxic drugs during the entire
study period and none of them experienced infections
or malignancy.
The phosphatemia decreased after 2 years in each
group, significantly in Group A (-0.5 mg/dL, p = 0.0058)
and Group C (-0.5, p = 0.0128). There were no signifi-
cant differences between Group A and B, and Group C
and D. Five patients developed a grade 1 or 2 DAIDS
hypophosphatemia event; among these, 4 were treated
with TDF+PI and one only with TDF. Phosphorus levels
came back to normal without discontinuing the therapy.
Among these patients two were HCV co infected, not
taking any HCV treatment, and one patient experienced
Burkitt Lymphoma and underwent chemotherapy.
Discussion
Our study describes for the first time in a controlled
study, the role of TDF and the concomitant use of TDF
and PI in HIV-infected paediatric patients. The long
term impact of ARV, specifically of drugs associated
with renal damage on adults, is a major topic in infected
children, since they are expected to have a longer dura-
tion of exposure. Moreover registration studies of anti-
retrovirals in children are few, with limited time of
observation, and are often not focused on drugs
interaction.
We reported a significant variation in the eGFR after 2
years in the entire cohort (p = 0.006) with a mean net
loss of 12.1 ml/min per 1.73 m2, confirming what was
reported by other studies on HIV infected adults
[24,25]. We didn’t find any significant eGFR variation in
patients taking TDF+PI or TDF, even when compared
to the group that was not treated with nor TDF nor PI,
or TDF respectively. However, all three of the cases who
developed a mild reduction in eGFR were on a regimen
containing both TDF and PI.
This is consistent with two other studies on ARV-
experienced children treated with TDF-containing regi-
mens which didn’t find evidence of impaired filtration
rate, even if their sample sizes were very small (27 and
26 children respectively) and were not controlled
[13,14], and with other pediatric cohort studies report-
ing some cases of renal toxicity associated with TDF
[26-28]. Furthermore, as reported in other studies, esti-
mated eGFR cannot be considered a sensitive indicator
of early renal damage related to TDF [29], and our
observation could have been affected by limited sample
size. In fact, other studies on adults, with a large cohort
and a higher power, found that patients treated with
TDF and PI based regimens had a significantly greater
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decline in renal function than those taking TDF with
Non-NRTIs (NNRTIs) or non-TDF-based regimens
[25,30]. The role of co-administration of TDF and PI on
renal function was also recently demonstrated in a large
randomized clinical trial on 1858 ART-naïve adults, the
ACTG 5202 study, comparing four different regimens
(TDF+NNRTI; TDF+PI; other NRTIs+NNRTI; otherNR-
TIs+PI). In this study the only regimen with a signifi-
cant reduction in estimated creatinine clearance was in
the group on both TDF and PI [31].
The detection of early or mild TDF-related nephro-
toxicity could be evaluated with other more specific
tests for proximal tubule injury, such as serum phos-
phate and potassium levels.
In our study we didn’t find any significant variation in
potassium in all therapy groups, but there was a trend
in reduction in Group C (TDF+PI) after 2 years, and
this variation resulted significantly different if compared
to the Group D (no TDF+PI). This seems to confirm
what has been already demonstrated by observations in
adults and in pediatric population on TDF [12,26].
In healthy population serum phosphorus is slightly
higher in the prepubertal age, decreasing to adult values
after puberty, as also considered by the age-specific
DAIDS event scale. A recent case-control study in chil-
dren confirmed an association between the use of TDF
and hypophosphatemia, but it didn’t analyze the role of
concomitant use of PI [17]. In our analysis the levels of
phosphatemia changed earlier (after 1 year) and signifi-
cantly in the entire cohort. Moreover phosphate reduc-
tion resulted significant and worse in the group treated
with TDF, and in the group treated with TDF and PI;
notably four of the five patients who developed clinical
hypophosphataemia were on this regimen.
The observation of a tubular damage associated with
concomitant use of TDF and PI is consistent with
pathogenetic cellular studies and PK analysis, showing
that PI inhibition of MRP2 and MRP4 results in an
increase of tubular concentration of TDF [22,23,32], and
TDF clearance is slower in subjects receiving PI, with an
AUC increased of 22-37%, and possible increase of
mitochondrial damage [21].
Table 1 Baseline characteristics of the patients, overall and in each treatment group
Total
n.49














Female n (%) 28 (57%) 18 (58%) 10 (56%) 0.86 12 (52%) 16 (62%) 0.51
Age Mean (SD) 13.6 (± 2.5) 14.0 13.0 0.18 14.1 (± 2.7) 13.2(± 2.3) 0.20
HIV < 50 copies/mL 23 (47%) 12 (39%) 11 (61%) 0.13 9 (39%) 14 (54%) 0.30
CD4% (SD) 27.1 (± 10.2) 24.7 (± 10.4) 31.8 (± 8.3) 0.04 23.6 (± 10.5) 30.7 (± 8.8) 0.02
Ethnicity (Africa) 8 (16%) 3 (10%) 5 (28%) 0.10 2(9%) 6 (23%) 0.17
eGFR at baseline median
ml/min per 1.73 m2(IQR)
143.6 (124.5-167.4 143.6 (123.7-165.4) 147.5 (124.5-169.6) 0.48* 135.0 (122.2-156.0) 152.6 (128.0-169.6) 0.14*
Phosphatemia at baseline
Median mg/dl (IQR)
4.4 (3.8-5.0) 4.4 (3.8-5.0) 4.7 (3.8-5.2) 0.30* 4.4 (3.9-5.0) 4.5 (3.8-5.1) 0.44*
Years on current
regimen mean (SD)
1.11 (1,64) 0,76 (1,30) 1,71 (1,99) 0.06 1 (1,41) 1,21 (1,84) 0.67
ART regimen
TDF+FTC+LPV/r 10 (20%) 10 (32%) - - 10 (43%) -
TDF+FTC+ATV/r 11 (22%) 11 (35%) - - 11 (48%) -
TDF+FTC+Other PI/r 2 (4%) 2 (6%) - - 2 (9%) -
ABC+3TC+LPV/r 6 (12%) - 6 (33%) - - 6 (23%) -
ABC+3TC+other PI 4 (8%) - 4 (22%) - - 4 (15%) -
3TC+ABC+EFV 7 (14%) - 7 (39%) - - 7 (27%) -
ABC+3TC+AZT 1 (2%) - 1 (6%) - - 1 (4%) -
TDF+ABC+EFV 1 (2%) 1 (3%) - - - 1 (4%) -
TDF+FTC+EFV 7 (14%) 7 (23%) - - - 7 (27%) -
SD Standard Deviation; p value calculated with ANOVA or with Mann Whitney test (*) and was referred to comparison between baseline variable of Group A
versus Group B, or Group C versus Group D. TDF Tenofovir Disoproxil Fumarate; FTC= Emtricitabine; LPV/r = Lopinavir/ritonavir; ATV/r Atazanavir/ritonavir; PI/r=
Ritonavir boosted Protease Inhibitors; ABC= Abacavir; 3TC= Lamivudine; EFV= Efavirenz; AZT= Zidovudine; OT Other Treatments; r= ritonavir; IQR interquartile
range
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However our analysis has some limitations: it is an
observational study, and although the groups analyzed
resulted not different for age, gender, HIV or ethnicity,
other variables like immune status and disease progres-
sion, could have had a role. Furthermore we assessed
renal impairment without analyzing urine tests and other
more sensitive indicators such as b-2 microglobulinuria
that may have shown some milder renal abnormalities.
Moreover, we didn’t assess the association of TDF and PI
with lower bone mineral density as reported by other stu-
dies [13,17,33], and the clinical significance of kidney
abnormalities observed remains not fully known. Further
studies with more sensitive urine markers, bone density
assays, and longer follow-up are warranted.
Conclusion
In conclusion, this study highlights that in HIV infected
children and adolescents on ART, renal function and
phosphatemia decreased over time. Cases of hypopho-
sphatemia and mild reduction of eGFR observed in
patients on TDF+PI suggest an association between this
ART regimen and renal function, however this appears
weak and not confirmed in the subgroup analysis. New
studies, with more sensitive methods and larger number,
focused on the effect of these regimens on renal function
of HIV infected children are warranted.
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Figure 1 Renal function and tubular damage markers, at baseline and after 1 and 2 years, in the entire cohort, and in each treatment
group. Patients were grouped according to the exposure to antiretrovirals: Group A = TDF, Group B = no TDF; Group C = TDF+PI, Group D =
no TDF+PI. Statistical analysis related to baseline, 1 and 2 years in each group were performed through Friedman test. P-values related to
analysis between group A versus group B and group C versus group D at each time point were obtained through Mann Whitney test (*), while
those related to analysis between two time points among the same group with Wilcoxon matched-paired signed rank test (#).
Pontrelli et al. BMC Infectious Diseases 2012, 12:18
http://www.biomedcentral.com/1471-2334/12/18
Page 5 of 6
References
1. D’Arminio Monforte A, Sabin CA, Phillips A, et al: The changing incidence
of AIDS events in patients receiving highly active antiretroviral therapy.
Arc Intern Med 2005, 165:416-423.
2. Chiappini E, Galli L, Tovo PA, et al: Changing patterns of clinical events in
perinatally HIV-1-infected children during the era of HAART. AIDS 2007,
21:1607-1615.
3. Guideline on the clinical development of medical products for the
treatment of HIV infection. [http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2009/09/WC500003399.pdf].
4. Roling J, Schmid H, Fischereder M, et al: HIV-Associated Renal Diseases
and Highly Active Antiretroviral Therapy-Induced Nephropathy. Clin
Infect Dis 2006, 42:1488-1495.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the use of antiretroviral agents in HIV-1-infected adults
and adolescents. Department of Health and Human Services 2011, 1-166,
Available at [http://www.aidsinfo.nih.gov/ContentFiles/
AdultandAdolescentGL.pdf].
6. Lee JC, Marosok RD: Acute tubular necrosis in a patient receiving
tenofovir. AIDS 2003, 17:2543-2544.
7. Creput C, Gonzalez-Canali G, Hill G, et al: Renal lesions in HIV-1-positive
patient treated with tenofovir. AIDS 2003, 17:935-937.
8. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, et al: Tenofovir related
nephrotoxicity in HIV-infected patients. AIDS 2004, 18:960-963.
9. Zimmermann AE, Pizzoferrato T, Bedford J, et al: Tenofovir-associated
acute and chronic kidney disease: a case of multiple drug interactions.
Clin Infect Dis 2006, 42:283-290.
10. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, et al: Drug induced Fanconi’s
syndrome. Am J Kidney Dis 2003, 41:292-309.
11. Gupta SK: Tenofovir-associated Fanconi syndrome: review of the FDA
adverse event reporting system. AIDS Patient Care STDS 2008, 22:99-103.
12. Cirino CM, Kan VL: Hypokalemia in HIV patients on tenofovir. AIDS 2006,
20(12):1671-1673.
13. Hazra R, Gafni RI, Maldarelli F, et al: Tenofovir disoproxil fumarate and an
optimized background regimen of antiretroviral agents as salvage
therapy for pediatric HIV infection. Pediatrics 2005, 116(6):846-854.
14. Viganò A, Bedogni G, Manfredini V, et al: Long-term renal safety of
tenofovir disoproxil fumarate in vertically HIV-infected children,
adolescents and young adults: a 60-month follow-up study. Clin Drug
Investig 2011, 31(6):407-415.
15. Hussain S, Khayat A, Tolaymat A: Nephrotoxicity in a child with perinatal
HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol 2006,
21:1034-1036.
16. Rollot F, Nazal E, Chauvelot-Moachon L, et al: Tenofovir-related Fanconi
syndrome with nephrogenic diabetes insipidus in a patient with
acquired immunodeficiency syndrome: the role of lopinavir-
ritonavirdidanosine. Clin Infect Dis 2003, 37:174-176.
17. Judd A, Boyd KL, Stöhr W, et al: Effect of tenofovir disoproxil fumarate on
risk of renal abnormality in HIV-1-infected children on antiretroviral
therapy: a nested case-control study. AIDS 2010, 24(4):525-534.
18. Purdy JB, Gafni RI, Reynolds JC, et al: Decreased bone mineral density
with off-label use of tenofovir in children and adolescents infected with
human immunodeficiency virus. J Pediatr 2008, 152:582-584.
19. Rodriguez-Novoa S, Labarga P, Soriano V: Pharmacogenetics of tenofovir
treatment. Pharmacogenomics 2009, 10(10):1675-1685.
20. Kiser JJ, Carten ML, Aquilante CL, et al: The effect of lopinavir/ritonavir on
the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol
Ther 2008, 83(2):265-272.
21. Viread: SUMMARY OF PRODUCT CHARACTERISTICS. European Medicines
Agency [http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR__Product_Information/human/000419/WC500051737.pdf pag.8].
22. Kiser JJ, Fletcher CV, Flynn PM, et al: Pharmacokinetics of antiretroviral
regimens containing tenofovir disoproxil fumarate and atazanavir-
ritonavir in adolescents and young adults with human
immunodeficiency virus infection. Adolescent Trials Network for HIV/
AIDS Interventions. Antimicrob Agents Chemother 2008, 52(2):631-637.
23. Robertson EE, Ranking GO: Human renal organic anion transporters:
characteristics and contributors to drug and drug metabolite excretion.
Pharmacol Ther 2006, 109:383-389.
24. Gallant JE, Moore RD: Renal function with use of a tenofovir-containing
initial antiretroviral regimen. AIDS 2009, 23:197-1975.
25. Campbell LJ, Ibrahim F, Fisher M, et al: Spectrum of chronic kidney
disease in HIV-infected patients. HIV Med 2009, 10(6):329-336.
26. Riordan A, Judd A, Boyd K, et al: Tenofovir use in Human
immunodeficiency virus-1-infected children in the United Kingdom and
Ireland. Pediatr Infect Dis J 2009, 28:204-209.
27. Hussain S, Khayat A, Tolaymat A, et al: Nephrotoxicity in a child with
perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr
Nephrol 2006, 21(7):1034-1036.
28. Soler-Palacín P, Melendo S, Noguera-Julian A, et al: Prospective study of
renal function in HIV-infected pediatric patients receiving tenofovir-
containing HAART regimens. AIDS 2011, 25(2):171-176.
29. Labarga P, Barreiro P, Martin-Carbonero L, et al: Kidney tubular
abnormalities in the absence of impaired glomerular function in HIV
patients treated with tenofovir. AIDS 2009, 23(6):689-696.
30. Goicoechea M, Liu S, Best B, et al: Greater tenofovir-associated renal
function decline with protease inhibitor-based versus nonnucleoside
reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008,
197:102-108.
31. Daar E, Tierney C, Fischl M, et al: ACTG 5202: final results of ABC/3TC or
TDF/FTC with either EFV or ATV/r in treatment-naive HIVinfected
patients. [Abstract 59LB.]. 17th Conference on Retroviruses and Opportunistic
Infections San Francisco, CA; 2010.
32. Kiser JJ, Aquilante CL, Anderson PL, et al: Effect of Multidrug resistance
proteins 2 and 4 polymorphisms on tenofovir pharmacokinetics in HIV-
infected patients. 7th International Workshop on Clinical Pharmacology of
HIV Therapy Lisbon, Portugal; 2006.
33. Giacomet V, Mora S, Martelli L, et al: A 12-month treatment with tenofovir
does not impair bone mineral accrual in HIV-infected children. J Acquir
Immune Defic Syndr 2005, 40:448-450.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/12/18/prepub
doi:10.1186/1471-2334-12-18
Cite this article as: Pontrelli et al.: Renal function in HIV-infected
children and adolescents treated with tenofovir disoproxil fumarate and
protease inhibitors. BMC Infectious Diseases 2012 12:18.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pontrelli et al. BMC Infectious Diseases 2012, 12:18
http://www.biomedcentral.com/1471-2334/12/18
Page 6 of 6
